Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andriy Krendyukov

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 2, 2018
Correction to: Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience GainedMatti Aapro, Andriy Krendyukov, Martin Schiestl, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 9, 2018
Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience GainedMatti Aapro, Andriy Krendyukov, Martin Schiestl, et al.
Leukemia Research|April 22, 2019
Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocolsPere Gascón, Andriy Krendyukov, Nicola Mathieson, et al.
Frontiers in Oncology|November 17, 2022
Early access provision: Awareness, educational needs and opportunities to improve oncology patients' access to careAndriy Krendyukov, Sanjay Singhvi, Yianick Green-Morrison, et al.
Cancer Management and Research|March 24, 2021
CD95L and Anti-Tumor Immune Response: Current Understanding and New EvidenceDavid M Richards, Christian Merz, Christian Gieffers, et al.
Pharmaceutical Medicine|June 4, 2026
Optimising Formulations for Paediatric Patients with Inherited Metabolic Disorders: The Case Study of LevocarnitineStephen Tomlin, Chris Mühlhausen, Andriy Krendyukov, et al.
Future Oncology (London, England)|May 23, 2019
Meta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancerBernardo Rapoport, Ramin B Arani, Nicola Mathieson, et al.
Clinical Drug Investigation|March 4, 2018
Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?David Goldsmith, Frank Dellanna, Martin Schiestl, et al.
Journal of Neuro-Oncology|November 4, 2019
Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patientsWolfgang Wick, Andriy Krendyukov, Klaus Junge, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 24, 2019
Extrapolation in Practice: Lessons from 10 Years with Biosimilar FilgrastimPere Gascon, Andriy Krendyukov, Nicola Mathieson, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 2, 2018
Correction to: Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience GainedMatti Aapro, Andriy Krendyukov, Martin Schiestl, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 9, 2018
Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience GainedMatti Aapro, Andriy Krendyukov, Martin Schiestl, et al.
Leukemia Research|April 22, 2019
Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocolsPere Gascón, Andriy Krendyukov, Nicola Mathieson, et al.
Frontiers in Oncology|November 17, 2022
Early access provision: Awareness, educational needs and opportunities to improve oncology patients' access to careAndriy Krendyukov, Sanjay Singhvi, Yianick Green-Morrison, et al.
Cancer Management and Research|March 24, 2021
CD95L and Anti-Tumor Immune Response: Current Understanding and New EvidenceDavid M Richards, Christian Merz, Christian Gieffers, et al.
Pharmaceutical Medicine|June 4, 2026
Optimising Formulations for Paediatric Patients with Inherited Metabolic Disorders: The Case Study of LevocarnitineStephen Tomlin, Chris Mühlhausen, Andriy Krendyukov, et al.
Future Oncology (London, England)|May 23, 2019
Meta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancerBernardo Rapoport, Ramin B Arani, Nicola Mathieson, et al.
Clinical Drug Investigation|March 4, 2018
Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?David Goldsmith, Frank Dellanna, Martin Schiestl, et al.
Journal of Neuro-Oncology|November 4, 2019
Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patientsWolfgang Wick, Andriy Krendyukov, Klaus Junge, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 24, 2019
Extrapolation in Practice: Lessons from 10 Years with Biosimilar FilgrastimPere Gascon, Andriy Krendyukov, Nicola Mathieson, et al.
Pageof 4